A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

ClinicalTrials.gov ID: NCT07780669

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07780669. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Study identification

NCT ID: NCT07780669
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 624 participants

Conditions and interventions

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Drug

Eligibility (public fields only)

Age range: 40 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 27, 2026 (Actual)
Primary completion: Jul 20, 2029 (Estimated)
Completion: Mar 15, 2030 (Estimated)
Last update posted: Nov 12, 2026

2026 – 2030

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
GSK Investigational Site	Doral	Florida	33172	Recruiting
GSK Investigational Site	Derby	Kansas	67037	Recruiting
GSK Investigational Site	Lake Charles	Louisiana	70605	Recruiting
GSK Investigational Site	Staten Island	New York	10309	Recruiting
GSK Investigational Site	Humble	Texas	77396	Recruiting
GSK Investigational Site	Huntsville	Texas	77340-2781	Recruiting
GSK Investigational Site	West Jordan	Utah	84088-8857	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07780669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 15, 2026